SEC Form 4 · accession 0001700659-26-000012
REGENXBIO Inc. · RGNX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steve Pakola
Officer — Chief Medical Officer
Period of report
Jun 29, 2026
Accepted (ET)
Jul 1, 2026 · 8:08 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001590877
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jun 29, 2026 | S | 19,608 | $11.04 | D | 213,009 | D | |
| Common Stock | Jul 1, 2026 | M | 36,725 | $7.86 | A | 249,734 | D | |
| Common Stock | Jul 1, 2026 | S | 36,725 | $12.86 | D | 213,009 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to Buy)F3 | $7.86 | Jul 1, 2026 | M | 36,725 | D | — | Jan 2, 2035 | Common Stock | 36,725 | 66,973 | D |
Explanation of responses
- F1This transaction was effected pursuant to a Rule 10b5-1 trading plan.
- F2This transaction was executed in multiple trades at prices ranging from $11.00 to $11.18. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3The previously granted option, representing a right to purchase a total of 103,698 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 2, 2026, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer